Carolinas Wealth Consulting’s Revance Therapeutics, Inc. RVNC Stock Holding History

Carolinas Wealth Consulting’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-112	Closed	-$341	–	1107
2024 Q4	$341	Hold	112	–	–	﹤0.01%	1035
2024 Q3	$582	Hold	112	–	–	﹤0.01%	992
2024 Q2	$288	Hold	112	–	–	﹤0.01%	1018
2024 Q1	$551	Buy	+112	New	+$663	﹤0.01%	971

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Carolinas Wealth Consulting's RVNC Position: Q1 2025 in Review

Carolinas Wealth Consulting sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 112 shares — an estimated $341 sold.

Carolinas Wealth Consulting first reported a position in RVNC in Q1 2024 and held it in 4 quarters. The position peaked at $582 in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Carolinas Wealth Consulting reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Carolinas Wealth Consulting sold 112 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $341.
Carolinas Wealth Consulting first reported a position in Revance Therapeutics, Inc. in Q1 2024 and held it in 4 quarters.
Carolinas Wealth Consulting's Revance Therapeutics, Inc. position peaked at $582 in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q1 2025, filed 14 Aug 2025.